Resultados relacionados
Resultados totales (Incluyendo duplicados): 2Encontrada(s) 1 página(s)
Set de datos (Dataset). 2026
Prognostic value of glycemic variability in acute ischemic stroke in the GLycemia In Acute Stroke (GLIAS) III study. Anonymised Dataset, Elena de Celis Ruiz, Silvia Pastor, Noemí González Pérez de Villar, María Martínez-Balaguer, Marimar Freijo, Mar Castellanos, Noemí Díez-González, María Santamaría, Laura Amaya-Pascasio, Arturo Fraga Bau, Raquel Delgado-Mederos, Ana Calleja, Juan Carlos Portilla, Ángeles Ortega-Casarrubios, Blanca Fuentes, on behalf of the GLIAS-III study Group Prognostic value of glycemic variability in acute ischemic stroke in the GLycemia In Acute Stroke (GLIAS) III study. Anonymised Dataset. RIMASalud. Version 1.0. 29/07/2026.
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
- de Celis-Ruiz, Elena
- Pastor, Silvia
- González Pérez de Villar, Noemí
- Martínez-Balaguer, María
- Freijo, Marimar
- Castellanos, Mar
- Díez-González, Noemí
- Santamaría, María
- Amaya-Pascasio, Laura
- Fraga-Bau, Arturo
- Delgado-Mederos, Raquel
- Calleja, Ana
- Portilla, Juan Carllos
- Ortega-Casarrubios, Mª Ángeles
- Fuentes, Blanca
This repository contains the anonymised participant-level dataset generated during the GLIAS-III study, a prospective multicentre observational cohort investigating continuous glucose monitoring (CGM), glycaemic variability and clinical outcomes in patients with acute ischaemic stroke. The dataset is made publicly available to promote transparency, reproducibility and secondary research while ensuring compliance with applicable ethical and data protection regulations., The repository contains the following files:
-GLIASIII_dataset.csv: Anonymised participant-level dataset.
-GLIASIII_Metadata.pdf: Complete metadata describing study design, methodology, variables, anonymisation procedures and data processing. It includes the Data Dictionary (definitions, coding and units)
-GLIASIII_README.txt: General information and instructions for dataset reuse.
-GLIASIII_dataset.csv: Anonymised participant-level dataset.
-GLIASIII_Metadata.pdf: Complete metadata describing study design, methodology, variables, anonymisation procedures and data processing. It includes the Data Dictionary (definitions, coding and units)
-GLIASIII_README.txt: General information and instructions for dataset reuse.
Proyecto: ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/PI18-00991
Artículo científico (JournalArticle). 2020
Glycemic variability, prognostic impact on acute ischemic stroke and the impact of corrective treatment for hyperglycemia. The GLIAS-III translational study
Dipòsit Digital de Documents de la UAB
- Fuentes, Blanca|||0000-0002-0363-862X
- Pastor-Yborra, Silvia
- Gutiérrez-Zúñiga, Raquel
- González-Pérez de Villar, Noemí
- Celis Ruiz, Elena de|||0000-0002-9224-9422
- Rodríguez-Pardo, Jorge
- Gómez-de Frutos, Mari Carmen
- Laso-García, Fernando
- Gutiérrez-Fernández, María
- Ortega-Casarrubios, MÁngeles
- Soto González, Alfonso
- López-Fernández, María
- Santamaría, María
- Díez-González, Noemí
- Freijo, Mar M.
- Zandio, Beatriz
- Delgado Mederos, Raquel|||0000-0003-3737-7226
- Calleja, Ana
- Portilla-Cuenca, Juan Carlos
- Lisbona, Arturo
- Otero-Ortega, Laura
- Díez-Tejedor, Exuperio
Glycemic variability (GV) represents the amplitude of oscillations in glucose levels over time and is associated with higher mortality in critically ill patients. Our aim is to evaluate the impact of GV on acute ischemic stroke (IS) outcomes in humans and explore the impact of two different insulin administration routes on GV in an animal model. This translational study consists of two studies conducted in parallel: The first study is an observational, multicenter, prospective clinical study in which 340 patients with acute IS will be subcutaneously implanted a sensor to continuously monitor blood glucose levels for 96 h. The second study is a basic experimental study using an animal model (rats) with permanent occlusion of the middle cerebral artery and induced hyperglycemia (through an intraperitoneal injection of nicotinamide and streptozotocin). The animal study will include the following 6 groups (10 animals per group): sham; hyperglycemia without IS; IS without hyperglycemia; IS and hyperglycemia without treatment; IS and hyperglycemia and intravenous insulin; and IS and hyperglycemia and subcutaneous insulin. The endpoint for the first study is mortality at 3 months, while the endpoints for the animal model study are GV, functional recovery and biomarkers. The GLIAS-III study will be the first translational approach analyzing the prognostic influence of GV, evaluated by the use of subcutaneous glucose monitors, in acute stroke. Trial registration (NCT04001049).